A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Psoriasis

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

J Eur Acad Dermatol Venereol.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB

doi: 10.1111/jdv.15258.

Acne

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials

JAMA Dermatol.

Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A

doi: 10.1001/jamadermatol.2020.0465.

Psoriasis

Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled Phase 4 trial

Eur J Dermatol

Liu L, Zhang C, Wang J, Chen K, Ding Y, Yan G, Lu Q, Li W, Fang H, Cheng H, Zhang J, He Y, Zhu W, Lu Y, Huang J, Pan W, Li M, Cao S, Li S, Han X, He L, Chen Y, Zheng M

doi: 10.1684/ejd.2020.3876

Psoriasis

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

JAMA Dermatol.

Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG

doi: 10.1001/jamadermatol.2020.0723.

Psoriasis

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Lancet

Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A

doi: 10.1016/S0140-6736(21)00126-4

Psoriasis

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H

doi: 10.1016/S0140-6736(18)31713-6.

Psoriasis

Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: Results from the randomized phase 3 CIMPACT trial

J Eur Acad Dermatol Venereol

Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, Arendt C, Fierens F, Blauvelt A

doi: 10.1111/jdv.17486

Psoriasis

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial

J Am Acad Dermatol.

Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA

doi: 10.1016/j.jaad.

Psoriasis

Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks from a Phase-3, Randomized, Placebo-Controlled Trial

J Eur Acad Dermatol Venereol.

Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B, Geng Z, Reyes Servin O, Rich PA

doi: 10.1111/jdv.15793.

Related content

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials

Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled Phase 4 trial

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: Results from the randomized phase 3 CIMPACT trial

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial

Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks from a Phase-3, Randomized, Placebo-Controlled Trial